These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25525598)

  • 1. Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra.
    Corradini BR; Iamashita P; Tampellini E; Farfel JM; Grinberg LT; Moreira-Filho CA
    Biomed Res Int; 2014; 2014():543673. PubMed ID: 25525598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease.
    Rousseaux MW; Marcogliese PC; Qu D; Hewitt SJ; Seang S; Kim RH; Slack RS; Schlossmacher MG; Lagace DC; Mak TW; Park DS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15918-23. PubMed ID: 23019375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.
    Bossers K; Meerhoff G; Balesar R; van Dongen JW; Kruse CG; Swaab DF; Verhaagen J
    Brain Pathol; 2009 Jan; 19(1):91-107. PubMed ID: 18462474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Pal GD; Ouyang B; Serrano G; Shill HA; Goetz C; Stebbins G; Metman LV; Driver-Dunckley E; Mehta SH; Caviness JN; Sabbagh MN; Adler CH; Beach TG;
    Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.
    Zarow C; Lyness SA; Mortimer JA; Chui HC
    Arch Neurol; 2003 Mar; 60(3):337-41. PubMed ID: 12633144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of Association of Locus Coeruleus Pathology with Orthostatic Hypotension in Parkinson's Disease.
    Tong Q; Chen L
    J Parkinsons Dis; 2021; 11(1):233-237. PubMed ID: 33104044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
    Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
    Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
    Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
    Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinson's disease.
    Sugama S; Sekiyama K; Kodama T; Takamatsu Y; Takenouchi T; Hashimoto M; Bruno C; Kakinuma Y
    Brain Behav Immun; 2016 Jan; 51():39-46. PubMed ID: 26291405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.
    Chiu CC; Lu CS; Weng YH; Chen YL; Huang YZ; Chen RS; Cheng YC; Huang YC; Liu YC; Lai SC; Lin KJ; Lin YW; Chen YJ; Chen CL; Yeh TH; Wang HL
    Mol Neurobiol; 2019 Jun; 56(6):3835-3853. PubMed ID: 30088174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Huynh B; Fu Y; Kirik D; Shine JM; Halliday GM
    Mov Disord; 2021 Sep; 36(9):2085-2093. PubMed ID: 33899954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.